A public health advocacy network has criticised a Maharashtra government Bill for omitting any provision to regulate the cost of treatment at private hospitals, arguing that the legislation leaves one of the most contested drivers of out-of-pocket healthcare expenses in the state entirely untouched.
The Jan Arogya Abhiyan (JAA), a coalition of organisations working on health rights, said the proposed Bill does not include mechanisms to cap, benchmark, or standardise treatment charges at private healthcare facilities. The criticism centres on what the group describes as a structural gap in a piece of legislation that the state government has framed as a major step toward patient protection and healthcare accountability. The group’s engagement comes at a stage when the Bill is under examination by a Joint Legislative Committee of the Maharashtra Legislature, the institutional forum where members of the ruling and opposition benches together scrutinise draft laws before they are placed before the Assembly for voting.
JAA has said it is conducting a series of engagements with members of the Maharashtra Legislative Assembly as part of its campaign on the Bill. According to the network, these include interactions with all 21 MLAs who sit on the Joint Legislative Committee (JLC) examining the proposed law. The number is significant because the JLC’s recommendations carry substantial weight over the final shape of the Bill, including the language of clauses, definitions of regulated entities, and the scope of penalties. A coordinated outreach to every member of the committee signals that JAA views this stage as the most consequential window for altering the legislation’s content.
Alongside its outreach to lawmakers, the network has called on the Maharashtra Health Minister to convene a statewide consultation with organisations, civil society networks, professional associations, and other stakeholders in the health sector to deliberate on the Bill before it is finalised. The demand for a formal consultation mechanism indicates that the group is seeking a structured channel for institutional input rather than relying solely on legislative lobbying. Such a consultation, if convened, would be expected to take submissions from patient groups, hospital associations, medical professionals, insurers, public health researchers, and state-level regulators before the JLC tables its report.
The Bill under discussion forms part of a broader effort by several Indian states to overhaul the regulatory architecture governing healthcare delivery, particularly after the Covid-19 pandemic exposed wide disparities in access, pricing, and quality between public and private providers. Multiple state governments have attempted to legislate on issues ranging from cross-subsidy requirements and price transparency in diagnostics to the regulation of commission-driven referrals and the rights of patients during admission and discharge. However, the actual capping of treatment rates charged by private hospitals has remained politically and economically sensitive, given the size of the private healthcare sector and the resistance of private hospital chains to state-determined tariffs.
JAA’s contention that the Bill does not regulate private hospital treatment rates draws attention to a recurring fault line in state-level healthcare legislation in India. While several laws and government orders have imposed ceilings on the cost of specific procedures, packages, or devices, comprehensive rate regulation across all categories of inpatient and outpatient treatment in private facilities has remained rare. Critics of unregulated private pricing have pointed to instances of wide variation in the cost of identical procedures within the same city, often attributed to differences in hospital classification, accreditation, and the negotiating capacity of insurers and corporate purchasers. Advocacy groups have also highlighted the financial burden placed on households without insurance coverage, who frequently bear the full cost of treatment at the point of service.
The Maharashtra Bill has been under discussion in political and policy circles for several months, with the state government describing it as a measure intended to strengthen patient rights, improve grievance redressal, and bring greater accountability to both public and private healthcare providers. The Bill’s specific provisions, scope of coverage, definitions of regulated entities, and enforcement mechanisms have been the subject of competing demands from industry bodies, civil society organisations, and medical professional associations. The Joint Legislative Committee’s examination is the formal mechanism through which these competing inputs are expected to be reconciled into a final legislative text.
By focusing its criticism on the absence of rate regulation, JAA has identified a clause-level concern rather than a wholesale rejection of the Bill. The distinction matters because it leaves open the possibility that the group is willing to support a revised version of the legislation that incorporates pricing controls, transparency requirements, or standardised treatment packages, provided such provisions are included through amendments or committee recommendations. The demand for a consultation with the Health Minister also suggests that the group is pursuing a procedural route, asking for stakeholder deliberation before the JLC finalises its recommendations.
Analysis:
Private healthcare costs have been a persistent source of public grievance in India, with multiple state governments facing criticism over the absence of standardised rate structures for procedures, diagnostics, and hospital stays. The criticism from a civil society network indicates that the Maharashtra Bill, as currently framed, may not resolve one of the most contested issues in state-level health policy. The demand for a statewide consultation suggests the advocacy group is seeking institutional leverage over the legislative process rather than direct opposition to the Bill.
The political economy of healthcare rate regulation in India is shaped by a small number of powerful private hospital chains, fragmented smaller nursing homes and clinics, and a large but unevenly distributed public health system. Any move to cap private treatment rates directly affects the revenue model of private providers, several of whom have argued in other states that price controls compromise quality, discourage investment, and lead to informal cost recovery through associated services. The repeated failure of rate regulation efforts at the state level has been attributed by analysts to the combined effect of industry lobbying, limited regulatory capacity, and the absence of standardised cost data on which tariffs can be based. The Maharashtra Bill’s omission of rate provisions, if confirmed in its final form, would place it alongside a growing list of state-level laws that promise patient protection without directly addressing the headline cost of treatment.
What to watch next:
The next significant milestone in the trajectory of the Bill will be the Joint Legislative Committee’s report and the accompanying recommendations, which are likely to indicate whether the JLC has accepted any of the submissions made by JAA or other stakeholders on the question of private hospital pricing. A decision by the Maharashtra Health Minister on whether to convene a statewide consultation, and the timing and scope of such a consultation, will be a key indicator of the government’s willingness to engage with civil society demands before the legislation is finalised. Any amendments to the Bill tabled in the Maharashtra Legislative Assembly, particularly those touching on pricing, transparency, or the regulation of private healthcare facilities, will determine the practical impact of the law on patient expenditure. The position taken by private hospital associations and medical professional bodies during the committee stage will also be a marker of the negotiating dynamics around any rate-related provisions.
Conclusion:
The criticism from Jan Arogya Abhiyan underscores a central tension in Maharashtra’s healthcare legislation: the gap between the political promise of patient protection and the absence of enforceable controls on private hospital pricing. The group’s engagement with all 21 members of the Joint Legislative Committee, combined with its demand for a statewide consultation under the Health Minister, reflects a coordinated effort to influence the Bill before its final form is decided. Whether the legislation emerges with any provision regulating the cost of treatment at private hospitals, or whether it proceeds without such provisions, will determine the extent to which the Bill addresses the financial burden that continues to drive healthcare-related distress across the state.
Sources:
The Hindu – https://www.thehindu.com/news/national/maharashtra/maharashtra-bill-does-not-regulate-private-hospital-treatment-rates-says-health-right-group/article71429540.ece
Source: The Hindu – National
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: The Hindu – National — source
